vimarsana.com

ஆஂடேரியொ மூளை நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KalGene Pharmaceuticals Inc an Alzheimer s focused company using a next generation engineered drug candidate, has appointed new leadership

KalGene Pharmaceuticals Inc an Alzheimer s focused company using a next generation engineered drug candidate, has appointed new leadership
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

10 Psychedelic Startups Investors are Flocking To

10 Psychedelic Startups Investors are Flocking To
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

Share this article Share this article LUCID s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback VANCOUVER, BC, April 21, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a partnership with LUCID Inc. ( LUCID ). LUCID s mission is to help people optimize their mental wellness through music, and they will be designing custom psychedelic music experiences for iSTRYM. After announcing its data partnership with Speak Ai last week, MINDCURE continues to integrate world-class technologies into and create proprietary experiences within iSTRYM, its psychedelics digital therapeutics platform. LUCID s platform is a key differentiator for iSTRYM as therapists and patients seek out scientifically validated tools to e

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.